A twist on an existing security technology will use enhanced mobile
phones to help establish the authenticity of pharmaceutical
products in developing countries.
UK drug goliath GlaxoSmithKline (GSK) is ramping up drug production
at its Polish site as it prepares to more than double the number of
markets the plant will supply.
Canadian contract manufacturer Patheon has announced a $150m
(€114m) investment by a private equity firm - a move the company
sees as the best viable option to end its financial misery.
Food and Drug Administration (FDA) staffing and timetabling
problems have delayed the re-inspection of Wyeth's Puerto Rico
site, the company said this week.
The US Food and Drug Administration (FDA) has given Baxter
Healthcare the go ahead for a modified version of the company's
Colleague volumetric infusion pump that was the subject of FDA
recalls and seizures in 2005 following...
UK firms Melbourn Scientific and Copley Scientific have agreed to
collaborate on developing novel methods of testing the force of
nasal sprays and metered-dose inhalers (MDIs).
Shire Pharmaceuticals' plans to buy New River Pharmaceuticals will
eventually affect a contract manufacturing arrangement with Albany
Molecular Research (AMR).
Ranbaxy has been granted an EU manufacturing and import license for
its Romania-based Terapia Ranbaxy subsidiary, and says it will make
the company a strategic regional hub for its operations in Europe.
German firm Sartorius has merged its biotech unit with
biopharmaceutical supplier Stedim Biosystems, forming a company
anticipated to generate sales of €400-420m during 2007.
Using contractors to fulfil packaging needs can significantly
reduce the time new products take to hit the market, claimed Gareth
Lewis of Cardinal Health, speaking at SMi's Pharmaceutical
Packaging and Labelling conference in...
Indian chemical firm Syschem is planning to splash out up to $15m
(€11.4m) over two years to expand its manufacturing capacity – a
move the company said will facilitate its smooth entry into the
pharma industry and help cope with...
Johnson Matthey's metal scavenging system, Smopex, is designed to
remove precious metals at high speed from solutions and active
pharmaceutical ingredients (APIs).
US firm Abraxis BioScience has been issued a firm warning by the
Food and Drug Administration (FDA) following concerns about
contamination of drug products and marketing violations for several
drugs.
Biotechnology firm Codexis has launched its Codex biocatalyst
panels, which promise to increase R&D and manufacturing
productivity while reducing cost.
The collaboration between DSM Pharmaceutical Products and
biotechnology firm Crucell has raised the bar for antibody
production, whilst decreasing manufacturing costs.
Invitrogen has decided to sell BioReliance, the 'beleaguered'
pharmaceutical services arm of its business, for less than half the
price they paid for it just three years ago.
Actavis has waded further into India and picked up new contract
manufacturing capabilities along the way with the purchase of a
division of Sanmar Specialty Chemicals (SSCL).
Australian contract manufacturing organisation (CMO) Eastland
Medical Systems has bagged a manufacturing and distribution
contract with UK's Proto-Pharma for its anti-malaria treatment.
Biotech contract manufacturer Diosynth and PDL Biopharma have
extended their agreement for the commercial supply of PDL's heart
attack treatment Retavase (reteplase), a move that signals the end
of manufacturing issues PDL experienced...
The International Society for Pharmaceutical Engineering (ISPE) has
released its latest industry guide, covering the commissioning and
qualification of pharmaceutical water and steam systems.
Albany Molecular Research (AMRI) has slipped again in the fourth
quarter of 2006 recording an operating loss of $2.5m (€1.9m) - six
per cent worse than the same quarter the previous year - despite
encouraging revenue growth in its...
A new partnership between India's Reliance Life Sciences (RLS) and
Ireland's GeneMedix will provide new contract opportunities for
European contract bio-manufacturers.
Italian contract manufacturer Procos has just opened a US office -
a move that will allow the company to offer custom synthesis
services directly to its US customers.
The US Food and Drug Administration (FDA) have issued
Kentucky-based Omnicare with a blunt warning letter outlining the
firm's quality and safety lapses at its repackaging facility in
Toledo.
Applied Biosystems are soon to launch their next generation genetic
analysis platform into a market that should allow a whole new wave
of biological understanding.
US-based sterile experts Mediatech has entered into a business
agreement with US-based packaging and filling supplier Rapak to
market and sell aseptic filling equipment to satisfy a gap in the
market.
This week Lonza took over the reigns of two new US business units
from Cambrex after completing the largest acquisition in its
company history and also announced a capability expansion at its
Czech Republic site.
Cardinal Health has reached an agreement with the US Food and Drug
Administration (FDA) on plans to resume manufacture and sale of its
Alaris (SE) line of infusion pumps. Units were seized and
production halted following grave safety...
MDS pharma has ceased operations at its bioanalytical services
facility in Blainville, Quebec in a bid to boost profitability
after an ongoing investigation of the site by the US Food and Drug
Administration (FDA).
Private pharmaceutical firm Tolmar has sold off its pharmaceutical
manufacturing plant in a move to fund the purchase of the US assets
of biopharmaceutical QLT. The plant, sold for $13.6m (€10.5m), will
be leased back to Tolmar under...
US-based biopharmaceutical product providers Millipore has met its
revenue and earnings target over the fiscal year, helped by its
Serologicals acquisition in the fourth quarter and a solid
performance by its main business driver:...
A UK-based firm is offering advice to chemical and pharmaceutical
companies on reducing hazardous waste and adhering to the
Registration, Evaluation and Authorisation of Chemicals Regulation
(REACH), which becomes law on 1 June 2007.
Pfizer's latest cutbacks will provide a new outsourcing opportunity
for contract manufacturing organisations (CMOs) in low-cost
destinations as the drug giant announces plans to double its amount
of drug production outsourcing.